Savara (SVRA) Gains from Sales and Divestitures (2016 - 2026)
Savara (SVRA) reported Gains from Sales and Divestitures of $125000.0 for Q1 2026, down 50.98% year-over-year from $255000.0 in Q1 2025, and down 94.18% quarter-over-quarter from $2.1 million in Q4 2025.
Savara (SVRA) Gains from Sales and Divestitures (2016 - 2026) Analysis & Trends
Savara (SVRA) has 11 years of Gains from Sales and Divestitures data on file, last reported at $125000.0 in Q1 2026.
- Gains from Sales and Divestitures for Q1 2026 came in at $125000.0, down 50.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $125000.0 (down 50.98% YoY), and the FY2025 annual result was $2.1 million, up 92.17% from the prior year.
- Gains from Sales and Divestitures retreated to $125000.0 in Q1 2026 per SVRA's latest filing, from $2.1 million in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $2.1 million in Q4 2025 and troughed at $1562.0 in Q2 2024.
- A 5-year average of $324077.3 and a median of $76563.0 in 2024 frame the typical range for Gains from Sales and Divestitures.
- The sharpest annual moves came in 2022 and 2025: Gains from Sales and Divestitures slumped 99.11% in 2022, then jumped 16214.78% in 2025.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $9125.0 in 2022, then surged by 11538.36% to $1.1 million in 2023, then grew by 5.25% to $1.1 million in 2024, then surged by 92.17% to $2.1 million in 2025, then tumbled by 94.18% to $125000.0 in 2026.
- Business Quant data shows SVRA's Gains from Sales and Divestitures at $125000.0 in Q1 2026, $2.1 million in Q4 2025, and $400000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 125,000.00 |
| Mar 31, 2026 | 125,000.00 |
| Dec 31, 2025 | 2.15 Mn |
| Dec 31, 2025 | 2.15 Mn |
| Sep 30, 2025 | 400,000.00 |
| Sep 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 125,000.00 |
| Jun 30, 2025 | 125,000.00 |
| Mar 31, 2025 | 255,000.00 |
| Mar 31, 2025 | 255,000.00 |
| Dec 31, 2024 | 1.12 Mn |
| Dec 31, 2024 | 1.12 Mn |
| Sep 30, 2024 | 76,563.00 |
| Sep 30, 2024 | 76,563.00 |
| Jun 30, 2024 | 1,562.00 |
| Jun 30, 2024 | 1,562.00 |
| Mar 31, 2024 | 1,563.00 |
| Mar 31, 2024 | 1,563.00 |
| Dec 31, 2023 | 1.06 Mn |
| Dec 31, 2023 | 1.06 Mn |